Answers are grounded in this paper and cite their sources.
Tamoxifen is widely used as adjuvant therapy for postmenopausal breast cancer patients with positive estrogen receptors. Data on a possible association of endometrial pathologies with tamoxifen treatment have been accumulating. In this review, we examine the current literature and include our own experience with this occurrence. We recommend close supervision of these patients.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: